Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma-Reference-Cited by-同舟云学术

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma

Published:2013-04-11 Issue:5 Volume:31 Page:403-413
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Greenhalgh Janette,Bagust Adrian,Boland Angela,Blundell Michaela,Oyee James,Beale Sophie,Dundar Yenal,Hockenhull Juliet,Proudlove Chris,Chu Patrick

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/article/10.1007/s40273-013-0043-8/fulltext.html

Reference55 articles.

1. National Institute for Health and Clinical Excellence. Guide to the single technology (STA) process. London: NICE; 2006. http://www.nice.org.uk/page.aspx?o=STAprocessguide . Accessed 1 Sep 2010.

2. Sculpher M. Single technology appraisal at the UK National Institute for Health and Clinical Excellence: a source of evidence and analysis for decision making internationally. Pharmacoeconomics. 2010;28(5):347–9.

3. Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(5):351–62.

4. Bagust A, Greenhalgh J, Boland A, et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(6):439–48.

5. Stevenson M, Pandor A. Febuxostat for the management of hyperuricemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(2):133–40.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review;Frontiers in Oncology;2023-08-23

2. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States;Leukemia & Lymphoma;2019-01-11

3. MODELING DISEASE PROGRESSION AND RISK-DIFFERENTIATED SCREENING FOR CERVICAL CANCER PREVENTION;Decision Analytics and Optimization in Disease Prevention and Treatment;2018-02-09

4. Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study);Pathology & Oncology Research;2017-04-21

5. Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies;ACTA CLINICA CROATICA;2017